Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the ...

It’s traditionally been particularly difficult to manage diabetes in highly active, still-developing children, but increasingly advanced glucose monitors and insulin delivery systems are aiming to ...

Available in Europe since 2020, this new system delivers the strongest clinical outcomes and best user experience to-date within the Medtronic family of pumps "Mealtimes prove to be one of the biggest ...

Medtronic plc MDT presented new clinical and real-world data on the MiniMed 780G system at the 83rd American Diabetes Association Scientific Sessions. In April, the FDA approved Medtronic's MiniMed ...

Medtronic plc MDT recently announced the receipt of the CE Mark for its next generation closed loop insulin pump system, MiniMed 780G, for the treatment of type 1 diabetes in the age range of 7 to 80 ...

Medtronic plc MDT recently announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic ...

Medtronic MDT is set to release second-quarter fiscal 2026 results on Nov. 18, before the market opens. The MedTech giant ...

Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...